Dong-A ST announced on October 27 that it has made a concerted effort to expand its global business at "CPHI Worldwide 2023".
CPHI is the world's largest pharmaceutical and biotechnology fair held annually in major European countries and attended by companies in all fields of pharmaceutical and biotechnology, including finished pharmaceuticals, raw materials, contract development manufacturing organizations (CDMOs), and contract research organizations (CROs).
Last year, more than 2,500 companies from more than 170 countries participated and more than 40,000 visitors attended the fair. This year, it was held in Barcelona, Spain, for three days from October 24 (Tuesday) to 26 (Thursday) local time.
Dong-A ST has participated every year since 2011, except for the 2020 and 2021 events, which were held online. Since 2013, the company has participated in a joint booth with ST Pharm.
The company participated again this year to promote Dong-A ST's R&D and production capabilities, as well as its own new and improved drugs, including diabetes drug Suganon, erectile dysfunction drug Zydena, and growth hormone drug Growtropin.
At the fair, Dong-A ST held business meetings with more than 150 pharmaceutical and biotech companies from 53 countries and explored various collaboration opportunities, including technology export and import, joint research, copyright export, and local production.
At the CPHI, Dong-A ST's President and CEO Park Jae-hong participated in the business meetings, while Dong-A Socio Holdings President Jung Jae-hoon, ST Pharm President Kim Kyung-jin, and STGEN Bio President Choi Kyung-eun also participated to promote the competitiveness of Dong-A ST and Dong-A Socio Group.
On October 24, Dong-A ST attended the "Accord Exclusive Partners Event" held by Accord Healthcare, which is responsible for the global sales of Stellara's biosimilar DMB-3115, to solidify the partnership with Accord Healthcare global partners for the sales of DMB-3115 in global markets including the United States and Europe.
On October 24, Dong-A ST signed a letter of intent (LOI) with Berko Pharma and Orphamed Pharma in Tunisia for the diabetes drug "Suganon", and plans to sign a distribution and export agreement this year.
On October 25, the company signed a license and export agreement for "Suganon" and "Zydena" with Jordan's Nairoukh Pharma and its affiliate Misk Pharmaceutical. With the signing of these agreements, DONG-AEST expands its global business to Europe and the Middle East, led by Tunisia and Jordan, respectively, and takes a step forward in entering the global pharmaceutical market.
